Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Stock Report

| More

CuraTeQ submits its first biosimilar filing with European Medicines Agency

Posted On: 2021-09-22 22:44:06 (Time Zone: IST)

Aurobindo Pharma Limited (along with its subsidiaries together referred to as "Aurobindo") has announced that its subsidiary CuraTeQ Biologics Pvt Ltd. (CuraTeQ) has submitted Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for BP14, an oncology biosimilar product.

"The submission of BP14 MAA with EMA is an important beginning in our business evolution and positions CuraTeQ well in our mission of providing access to high quality biosimilars for cancer patients. We remain on track for filing oursecond product, another oncology biosimilar in the regulated markets, in this calendar year.

Earlier, we completed a successful Phase 1 clinical trial of a monoclonal antibody biosimilar product used for the treatment of multiple types of cancers. Another biosimilar from our oncology portfolio, currently in Phase 3 clinical studies has reached the 50% patient recruitment milestone this month and we hope to complete the recruitment in the next two quarters. Our focus on executing parallel clinical studies for multiple biosimilars in oncology segment is a testament of our commitment in expanding biosimilars treatment options for patients suffering from debilitating diseases," said Dr. Satakarni Makkapati, CEO of CuraTeQ.

Mr. K. Nithyananda Reddy, Vice Chairman, Aurobindo said, "I am pleased to see that our commitment to biosimilars business, backed by world-class infrastructure and high caliber team is starting to see positive momentum with our first regulatory filing, with more products in licensure clinical trials. Through CuraTeQ, we aim to develop biosimilars for strengthening our focus in oncology and immunology segments. In a relatively short time span, the progression of our biosimilars pipeline is encouraging and we look forward to commercialize these products through our established commercial presence across the globe."

Shares of Aurobindo Pharma Ltd. was last trading in BSE at Rs. 731 as compared to the previous close of Rs. 726.35. The total number of shares traded during the day was 56536 in over 1702 trades.

The stock hit an intraday high of Rs. 733.8 and intraday low of 719.95. The net turnover during the day was Rs. 41102849.

Click here to send ur comments or to

Other Headlines:

Dr. Reddy's Laboratories launches Carmustine for Injection, USP in the U.S. Market

Karnataka Bank lays foundation stone for proposed Centenary Building

DOT approves Optiemus Group company's PLI scheme

HFCL Ltd arm gets approval for availing benefits under PLI scheme

Knowledge Marine & Engineering Works Limited purchases vessel TSHD Cauvery

SRF Ltd allots 23,69,80,820 Bonus Equity Shares

Steel Exchange India Limited board approves preferential issue of warrants, CCDs

Karnataka Bank gets new Chairman

California Software Company Ltd Q2FY22 consolidated PAT at Rs. 2.68 crore

Radhika Jeweltech Ltd board to consider migration from SME platform

M M Forgings Limited to acquire Cafoma Autoparts Private Limited

L&T launches L&T EduTech

PTC India Financial Services Ltd announces expiry of tenure of Mrs. Pravin Tripathi

Shilpa Medicare raises over Rs. 297 crore from marquee investors

Metropolis Healthcare Ltd revises terms of acquisition of Hitech

AF Enterprises Ltd allots 10 lakh shares

Trident Group Commissions Solar Power Plant at Budhni, Madhya Pradesh

Ircon International Ltd bags contract for Rs. 11.74 crore

National Fertilizers Ltd appoints additional director

Rain Industries Limited arm completes upgradation project of cement plant

EKI Energy Services Ltd defers stake acquisition in Sustainplus Rise Pvt Ltd

Soma Textiles & Industries Limited announces resignation of CFO

Balu Forge Industries Ltd executes agreement with Hilton Metal Forging Ltd

Moschip Technologies unveils Multi-Protocol long range 8G SerDes PHY in 28nm

Eco Recycling Ltd Q2FY22 consolidated net profit slides QoQ

Ind-Ra affirms rating of PNB Gilts Ltd

Capital India Finance Ltd receives approval for inward crossborder money transfer

Kotak Partners India SME Forum to Give a Boost to Indian Exports

Dixon Electro Appliances, received approval under PLI scheme of Government of India

HCL Technologies to evolve Long Term Incentive Plan, replacing portion of Cash Compensation with RSUs

Lloyds Steels Industries Ltd appoints additional director

Grasim Industries Limited announces resignation of Shri Vipin Anand

HCL Technologies Ltd board declares interim dividend of Rs. 10 for FY22

Shilpa Medicare Limited approves preferential allotment to investors

Lloyds Steels Industries Limited board approves preferential allotment, capacity expansion

Indiabulls Real Estate Ltd consolidated Q2FY22 net profit at Rs. 5.53 crore

Den Networks Ltd Q2FY22 consolidated net profit slips QoQ to Rs. 39.39 crore

Mahindra CIE Automotive Ltd consolidated Q3CY21 PAT at Rs. 166.32 crore

NBCC India secures total business of Rs. 2100.96 crore in September, 2021

Shri Gudey Srinivas appointed as Government Nominee Director in BPCL

Dhruv Consultancy Services Ltd receives LOA for consultancy services

Hero MotoCorp launches the new Xtreme 160R Stealth Edition

Godawari Power and Ispat Ltd fixes Oct 27, 2021 as record date for stock split, bonus issue

NR Agarwal Industries Ltd approves asset sale to Shree Ajit Pulp and Paper Ltd

Danlaw Technologies India Ltd announces resignation of MD

Inox Wind Ltd reports consolidated loss of Rs. 57.26 crores in Q2FY22

Golkonda Aluminium Extrusions Ltd posts Rs. 24.4 lakhs PAT in Q2 FY2021-22

Benares Hotels Ltd Q2FY22 PAT rises to Rs. 48.47 lakhs

Radhe Developers India Ltd Q2FY22 net profit at Rs. 9.11 crore

HCL Technologies Ltd posts consolidated PAT of Rs. 3259 crores in Q2FY22

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020